BridgeBio Pharma Inc.
BBIO | NASDAQ
$74.43
-$0.52 (-0.69%)
Nov 2, 2026, 9:33 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 502.08M | 221.9M | 9.3M | 77.65M | 69.72M | 8.25M |
Cost of Revenue | 28.27M | 3.88M | 2.45M | 3.43M | 3.11M | n/a |
Gross Profit | 473.81M | 218.02M | 6.86M | 74.21M | 66.6M | 8.25M |
Operating Income | -569.09M | -592.97M | -607.37M | -512.2M | -576.63M | -474.48M |
Interest Income | 19.85M | 17.25M | 18.04M | 7.54M | 1.13M | 4.02M |
Pretax Income | -734.99M | -542.19M | -653.25M | -484.65M | -586.45M | -505.49M |
Net Income | -729.31M | -535.76M | -643.2M | -481.18M | -562.54M | -448.72M |
Selling & General & Admin | 555.14M | 288.93M | 150.59M | 143.19M | 192.21M | 145.68M |
Research & Development | 477.54M | 506.46M | 455.71M | 399.46M | 451.02M | 337.05M |
Other Expenses | 10.22M | 15.61M | 7.93M | 43.77M | n/a | n/a |
Operating Expenses | 1.04B | 811M | 614.23M | 586.42M | 643.23M | 482.73M |
Interest Expense | 53.1M | 99.29M | 81.29M | 80.44M | 46.78M | 36.66M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.07B | 814.88M | 616.67M | 589.85M | 646.35M | 482.73M |
Income Tax Expense | 555K | 1.15M | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 197.24M | 186.08M | 162.79M | 147.47M | 144.36M | 118M |
Shares Outstanding (Diluted) | 197.24M | 186.08M | 162.79M | 147.47M | 144.36M | 118M |
EPS (Basic) | -3.79 | -2.88 | -3.95 | -3.35 | -3.90 | -4.10 |
EPS (Diluted) | -3.79 | -2.88 | -3.95 | -3.35 | -3.90 | -4.10 |
EBITDA | -676.45M | -436.83M | -565.47M | -397.44M | -533.83M | -467.38M |
EBIT | -681.88M | -442.9M | -571.96M | -404.21M | -539.68M | -468.83M |
Depreciation & Amortization | 5.43M | 6.08M | 6.49M | 6.77M | 5.84M | 1.46M |
Add to Watchlist
Select watchlists to add or remove BBIO